Hoth Therapeutics Signs a License Agreement with UMB and Isoprene Pharmaceuticals

Shots: 

• Hoth Therapeutics to get exclusive rights to evaluate UMB’s retinamides (RAMBAs) with an option to license the product to develop & commercialize therapies in the fields of dermatology and oncology 
• The focus of the agreement is to develop UMB’s novel retinamide Retinoic acid metabolism blocking agents (RAMBAs) therapies for cancer and dermatological diseases
• UMB’s RAMBAs are anticancer agents works against ATRA in cells providing therapeutic benefits to dermatological diseases including acne, eczema, psoriasis, cold sores, wounds, burns, sunburn, ichthyosis, skin cancer, and Kaposi’s Sarcoma

Click here to read full press release/ article | Ref: Hoth Therapeutics | Image: Plexuss